Linked Life Data

15325537

Source:http://linkedlifedata.com/resource/pubmed/id/15325537

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
2004-8-24
pubmed:abstractText
In clinical practice, neonatal polycythemia has been used as a marker for neonatal hyperviscosity, implicated as a cause of long-term neurologic delay and damage in the growing child. Clinicians have focused on the newborn infant's hematocrit (Hct) level as the criterion for therapeutic intervention. Partial exchange transfusion is traditionally used as the method to lower the Hct and treat hyperviscosity; however, it is unclear whether this is an effective approach in preventing the long-term neurologic consequences. This article re-evaluates this clinical approach to the diagnosis and treatment of neonatal polycythemia and suggests that this controversial therapy needs re-evaluation.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:status
MEDLINE
pubmed:month
Sep
pubmed:issn
0095-5108
pubmed:author
pubmed:issnType
Print
pubmed:volume
31
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
545-53, ix-x
pubmed:dateRevised
2005-11-16
pubmed:meshHeading
pubmed:year
2004
pubmed:articleTitle
Neonatal polycythemia: is partial exchange transfusion justified?
pubmed:affiliation
Department of Neonatology, Shaare Zedek Medical Center, Jerusalem 91031, Israel. schimmel@szmc.org.il
pubmed:publicationType
Journal Article, Review